Rchr
J-GLOBAL ID:200901040664676800   Update date: Jun. 28, 2024

Sekiguchi Fumiko

セキグチ フミコ | Sekiguchi Fumiko
Affiliation and department:
Job title: Associate Professor
Homepage URL  (1): http://www.phar.kindai.ac.jp/byoutai/
Research field  (1): Pharmacology
Research keywords  (7): HMGB1 ,  neuropathic pain ,  hydrogen sulfide ,  T-type calcium channel ,  プロテアーゼ活性化受容体 ,  Protection of gastic mucosa ,  Protease-activated receptor
Research theme for competitive and other funds  (17):
  • 2023 - 2026 The role of change in expression levels of coagulation factors in Schwann cells in the neuropathic pain
  • 2021 - 2024 血栓止血系分子とHMGB1の相互干渉による疼痛制御のメカニズムと臨床的意義の解明
  • 2020 - 2023 内因性硫化水素合成阻害による抗がん剤の有効性増大と副作用軽減の可能性について
  • 2017 - 2020 Novel therapeutic strategy targeting RAGE for treatment of peripheral neuropathy and visceral pain
  • 2017 - 2020 Study on the role of nuclear protein HMGB1 in the process of neurite regeneration after nerve injury
Show all
Papers (150):
  • Fumiko Sekiguchi, Maho Tsubota, Atsufumi Kawabata. Sulfide and polysulfide as pronociceptive mediators: Focus on Cav3.2 function enhancement and TRPA1 activation. Journal of pharmacological sciences. 2024. 155. 3. 113-120
  • Shiori Iwane, Wataru Nemoto, Tomoyoshi Miyamoto, Tomonori Hayashi, Masayuki Tanaka, Kazuki Uchitani, Tatsuya Muranaka, Masanori Fujitani, Yuichi Koizumi, Atsushi Hirata, et al. Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. Scientific Reports. 2024. 14. 1
  • Shiori Tomita, Fumiko Sekiguchi, Katsuki Naoe, Shiyu Shikimi, Yoshihito Kasanami, Maya Ohigashi, Maho Tsubota, Atsufumi Kawabata. Cav3.2-dependent hyperalgesia/allodynia following intrathecal and intraplantar zinc chelator administration in rodents. Journal of pharmacological sciences. 2023. 152. 2. 86-89
  • Fumiko Sekiguchi, Nene Koike, Yasuhiro Shimada, Kaho Sugimoto, Hiroshi Masuda, Takashi Nakamura, Hiroaki Yamaguchi, Genzoh Tanabe, Shinsuke Marumoto, Yoshihito Kasanami, et al. A hydrolysate of poly-trans-[(2-carboxyethyl)germasesquioxane] (Ge-132) suppresses Cav3.2-dependent pain by sequestering exogenous and endogenous sulfide. Redox biology. 2023. 59. 102579-102579
  • Takashi Maeda, Fumiko Sekiguchi, Kenji Mitani, Ryosuke Yamagata, Maho Tsubota, Shigeru Yoshida, Atsufumi Kawabata. Opioid modulation of T-type Ca2+ channel-dependent neuritogenesis/neurite outgrowth through the prostaglandin E2/EP4 receptor/protein kinase A pathway in mouse dorsal root ganglion neurons. Biochemical and biophysical research communications. 2023. 639. 142-149
more...
MISC (186):
  • 冨田詩織, 冨田詩織, 根本亙, 宮本朋佳, 宮本朋佳, 林友典, 田中雅幸, 打谷和記, 村中達也, 小泉祐一, et al. Effects of angiotensin converting enzyme inhibitors or receptor blockers on diabetic peripheral neuropathy: clinical evidence supported by a preclinical study. 日本薬学会年会要旨集(Web). 2023. 143rd
  • 冨田詩織, 冨田詩織, 宮本朋佳, 宮本朋佳, 田中雅幸, 打谷和記, 小泉祐一, 村中達也, 根本亙, 丹野孝一, et al. アンギオテンシン変換酵素阻害薬とアンギオテンシンII受容体拮抗薬は糖尿病性末梢神経障害の発症を抑制する:臨床・基礎融合研究によるエビデンス. 生体機能と創薬シンポジウム要旨集. 2022. 2022
  • 圓尾賢悟, 坪田真帆, 田島和樹, 関口富美子, 西堀正洋, 南達郎, 伊藤彰敏, 川畑篤史. Thrombomodulin alfaのoxaliplatin誘発性末梢神経障害抑制作用発現におけるHMGB1不活性化とprotein C及びTAFI活性化の相対的重要性と下流シグナル分子の解析. 日本薬理学雑誌. 2022. 157. Supplement
  • 堂本莉紗, 田村ひなの, 関口富美子, 坪田真帆, 西堀正洋, 川畑篤史. 抗リウマチ薬sulfasalazineはマクロファージからのHMGB1遊離を抑制することでlipopolysaccharide誘起アロディニアを抑制する. 日本薬理学雑誌. 2022. 157. Supplement
  • 岸本彩野, 堂本莉紗, 松永浩明, 松本亜紗菜, 坪田真帆, 関口富美子, 王登莉, 西堀正洋, 川畑篤史. Oxaliplatin誘起末梢神経障害には血小板由来HMGB1が関与する. 日本薬理学雑誌. 2022. 157. Supplement
more...
Patents (1):
Books (1):
  • Inhibitory role of nitric oxide in the contraction of circular muscle of rat portal vein(共著)
    The Bioloby of Nitric Oxide Part 6 Portland Press Ltd, London 1998
Lectures and oral presentations  (106):
  • Thrombomodulin/thrombin系で産生されるTAFIa/carboxypeptidase Bは補体成分C5aを不活性化することでoxaliplatin誘発性末梢神経障害を抑制する
    (第95回日本薬理学会年会. 福岡)
  • RAGE拮抗薬azeliragonはヒト前立腺がん由来LNCaP細胞の生存・増殖を抑制する:影響をうける細胞シグナルの解析
    (第95回日本薬理学会年会. 福岡)
  • 内因性H2S産生阻害による多発性骨髄腫細胞の生存抑制: カルビドパとベンセラジドのcystathionine-β-synthase阻害活性とボルテゾミブ耐性多発性骨髄腫治療への応用について
    (第95回日本薬理学会年会.福岡)
  • Schwann cells from neonatal;rat;sciatic nerves;secrete high mobility group box 1 (HMGB); a pro-inflammatory and pro-nociceptive mediator;in response to paclitaxel
    (12th FENS Forum of Neuroscience; Glasgow; UK. 2020)
  • Middle molecular weight heparinylphenylalanine selectively blocks RAGE and reduces HMGB1-dependent neuropathic and visceral pain in mice.
    (12th FENS Forum of Neuroscience, Glasgow, UK 2020)
more...
Education (2):
  • - 1991 The University of Tokushima Faculty of Pharmaceutical Sciences School of Pharmacy
  • - 1991 The University of Tokushima School of Pharmaceutical Sciences
Professional career (1):
  • Ph.D. (Kinki University)
Work history (9):
  • 2008/04 - 現在 Kinki University School of Pharmacy Pharmacology and Pathophysiology Associate Professor
  • 2007/04 - 2008/03 Kinki University School of Pharmacy Pharmacology and Pathophysiology lecturer
  • 2003/04 - 2007/03 Kindai University Faculty of Pharmacy
  • 2002/04 - 2003/03 Kindai University Faculty of Pharmacy
  • 2002 - 2003 Assistant Professor, Dept. Anat. and Physiol.,
Show all
Committee career (2):
  • 2002 - 日本平滑筋学会 評議員
  • 2002 - 日本薬理学会 評議員
Awards (2):
  • 2019/10 - 6th Congress of AsCNP Excellent Presentation Award for AsCNP2019, Category: Senior Researcher Paclitaxel, an anti-cancer drug, causes extracellular release of HMGB1, a pro-inflammatory and pro-nociceptive mediator, in Schwann cells derived from neonatal rat sciatic nerves.
  • 平成16(2004)年度 日本薬学会近畿支部奨励賞
Association Membership(s) (5):
Society for Neuroscience ,  日本疼痛学会 ,  日本薬学会 ,  日本平滑筋学会 ,  日本薬理学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page